Published in J Am Soc Nephrol on June 08, 2006
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat Immunol (2012) 1.97
Identification of common genetic variation that modulates alternative splicing. PLoS Genet (2007) 1.96
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol (2008) 1.69
aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol (2010) 1.67
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Gene conversion causing human inherited disease: evidence for involvement of non-B-DNA-forming sequences and recombination-promoting motifs in DNA breakage and repair. Hum Mutat (2009) 1.64
Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses. Immunity (2015) 1.60
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int (2010) 1.56
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood (2007) 1.53
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med (2011) 1.52
An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2015) 1.42
Genetic analysis of membrane cofactor protein (CD46) of the complement system in women with and without preeclamptic pregnancies. PLoS One (2015) 1.42
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2013) 1.32
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol (2012) 1.30
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol (2013) 1.14
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2012) 1.14
Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol (2014) 1.05
Membrane protein Crry maintains homeostasis of the complement system. J Immunol (2008) 1.04
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.03
A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.00
Atypical HUS and complement dysregulation. J Am Soc Nephrol (2006) 0.96
New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep (2014) 0.96
CD46-induced human Treg enhance B-cell responses. Eur J Immunol (2009) 0.94
Complement-dependent T-cell lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry. Blood (2009) 0.92
Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol (2011) 0.92
CD46 processing: a means of expression. Immunobiology (2011) 0.89
CD46 in innate and adaptive immunity: an update. Clin Exp Immunol (2011) 0.88
Gene conversion in human genetic disease. Genes (Basel) (2010) 0.85
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol (2012) 0.84
Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol (2013) 0.83
Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol (2012) 0.83
Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol (2010) 0.82
Complement regulator CD46: genetic variants and disease associations. Hum Genomics (2015) 0.82
Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri. Clin Kidney J (2014) 0.80
Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. PLoS Med (2006) 0.80
Complement modulation of T cell immune responses during homeostasis and disease. J Leukoc Biol (2014) 0.79
Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J (2016) 0.79
Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol (2013) 0.79
The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost (2016) 0.78
Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol (2011) 0.78
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) (2014) 0.77
A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica (2014) 0.76
Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant (2016) 0.76
Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods (2016) 0.76
Spontaneous abortion is associated with elevated systemic C5a and reduced mRNA of complement inhibitory proteins in placenta. Clin Exp Immunol (2014) 0.76
Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations. Pediatr Nephrol (2013) 0.76
Mutational analysis of Kaposica reveals that bridging of MG2 and CUB domains of target protein is crucial for the cofactor activity of RCA proteins. Proc Natl Acad Sci U S A (2015) 0.76
Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol (2017) 0.75
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest (2016) 0.75
Complement related kidney diseases: Recurrence after transplantation. World J Transplant (2016) 0.75
Whole-exome sequencing of a patient with severe and complex hemostatic abnormalities reveals a possible contributing frameshift mutation in C3AR1. Cold Spring Harb Mol Case Stud (2016) 0.75
Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection. CEN Case Rep (2012) 0.75
Occurrence of atypical HUS associated with influenza B. Eur J Pediatr (2017) 0.75
Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol (2015) 0.75
Favorable outcome in a case of Mycoplasma pneumoniae-associated crescentic glomerulonephritis. Pediatr Nephrol (2010) 0.75
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 3.99
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 2.83
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. Nat Genet (2002) 2.64
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 2.58
Adenovirus type 11 uses CD46 as a cellular receptor. J Virol (2003) 2.52
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med (2012) 2.51
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Online alcohol interventions: a systematic review. J Med Internet Res (2010) 2.37
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet (2007) 2.35
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol (2008) 2.30
T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2006) 2.27
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 2.00
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol (2008) 1.94
Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet (2008) 1.93
A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 1.89
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci (2009) 1.86
Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol Cell Biol (2002) 1.84
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol (2006) 1.81
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood (2010) 1.74
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Medication errors in hospitals: computerized unit dose drug dispensing system versus ward stock distribution system. Pharm World Sci (2003) 1.70
Acute renal infarction: a case series. Clin J Am Soc Nephrol (2012) 1.68
Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 1.67
Systematic planning of genome-scale experiments in poorly studied species. PLoS Comput Biol (2010) 1.66
A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol (2007) 1.66
Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis (2005) 1.62
Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun (2008) 1.57
Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol (2010) 1.55
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
Transcript signatures in experimental asthma: identification of STAT6-dependent and -independent pathways. J Immunol (2004) 1.54
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood (2007) 1.53
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med (2011) 1.52
Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol (2002) 1.51
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant (2007) 1.46
Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods (2011) 1.46
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med (2002) 1.42
Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics (2008) 1.41
Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. Soc Sci Med (2005) 1.39
CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol (2005) 1.37
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle (2008) 1.35
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One (2010) 1.33
CD46: expanding beyond complement regulation. Trends Immunol (2004) 1.32
Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev (2003) 1.30
Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol (2006) 1.29
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood (2012) 1.28
Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant (2008) 1.27
Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab (2011) 1.27
Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell (2002) 1.25
Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry (2005) 1.24
Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J Biol Chem (2001) 1.22
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med (2014) 1.21